Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571795 | 0.80 | ALDH1A1 (0.37) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL4060537 | 0.78 | TBXAS1 (0.39) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL7545549 | 0.77 | MMP1 (0.32) | KDM4EALDH1A1 | |
| SCHEMBL3734749 | 0.77 | ALDH1A1 (0.38) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL25475176 | 0.75 | TBXAS1 (0.33) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL16859466 | 0.75 | TBXAS1 (0.33) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL11048265 | 0.75 | TBXAS1 (0.33) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL16859463 | 0.75 | TBXAS1 (0.33) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL1487897 | 0.75 | ELANE (0.42) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL11589157 | 0.75 | TBXAS1 (0.44) | KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114980932-A | SORTILIN-binding conjugate compounds, compositions thereof, and their use for treating cancer | 瑟瑞技术公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114980932-A | SORTILIN-binding conjugate compounds, compositions thereof, and their use for treating cancer | 瑟瑞技术公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2011049836-A1 | ANTIBODY HEAVY CHAIN VARIABLE REGION (VH) DOMAIN EXCHANGE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110091992-A1 | CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT | MEDIMMUNE, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| EP-2078091-A2 | CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT | Medimmune, LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009009103-A2 | CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT | MEDIMMUNE, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1627046-A4 | DOMAIN-EXCHANGED BINDING MOLECULES, METHODS OF USE AND METHODS OF PRODUCTION | SCRIPPS RESEARCH INST (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7200493-B2 | Method for screening crystallization or amorphous stage conditions for molecules | CHEMICAL HOLOVOICE AB (SE) | 2007-04-03 | — | — | US | disclosed |
| EP-1627046-A2 | DOMAIN-EXCHANGED BINDING MOLECULES, METHODS OF USE AND METHODS OF PRODUCTION | The Scripps Research Institute (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050003347-A1 | Domain-exchanged binding molecules, methods of use and methods of production | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-06 | — | — | US | disclosed |
| WO-2004101738-A2 | DOMAIN-EXCHANGED BINDING MOLECULES, METHODS OF USE AND METHODS OF PRODUCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1360349-A1 | SYSTEM AND METHOD FOR SCREENING OF NUCLEATION TENDENCY OF A MOLECULE IN A LEVITATED DROPLET | Chemical Holovoice AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| US-20030049642-A1 | Screening system | NILSSON STAFFAN (SE) | 2003-03-13 | — | — | US | disclosed |
| WO-2002057520-A1 | SYSTEM AND METHOD FOR SCREENING OF NUCLEATION TENDENCY OF A MOLECULE IN A LEVITATED DROPLET | CHEMICAL HOLOVOICE AB (SE) | 2002-07-25 | — | — | WO | disclosed |